Malignant pleural mesotheliomas;Mesoteliomas malignos pleurales

Medicina

Volumn 58, Issue 6, 1998, Pages 699-706

  Mercurio, Sandra ^a   Poleri, Claudia ^a   Carassai, Monica ^a   Abdala, Oscar ^a   Lombardi, Dora ^a   Levy, Roberto ^a   Rojas, Oscar ^a   Morero, Jose ^a   Rosenberg, Moises ^a   López, Ana María ^b  

^a Inst Munic Rehabilitacion P   (Argentina)

^b NONE   (Argentina)

Author keywords

Asbestos; Mesotheliomas; Pleural tumors

Indexed keywords

DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PLEURA TUMOR; PROGNOSIS; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 0032233790     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. o IV, 3a. edición, 1992, p 2565-70.
2. Aisner J, Wiernik P. Malignant mesothelioma: current status and future prospects, Chest 1978; 74: 438-44.
3. Churg A. Malignant mesothelioma in British Columbia in 1982, Cancer 1985; 55: 672-4,
4. Scharifker D, Kaneco M. Localized fibrous mesothelioma of pleura. Cancer 43: 627.
5. Klemperer P, Rabin C. Primary neoplasms of the pleura. Report of five cases. Arch Pathol Lab Med 1937; 11: 385.
6. Wagner JC, Slaggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br J Ind Med 1960; 17: 260.
7. Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med 1965; 272: 560.
8. Hyers T, Ohar J, Crim C. Clinical controversies in asbestos-induced lung diseases. Seminars in Diagnostic Pathology 1992; 9: 97-101.
9. Bedrossian C, Bonsib S, Moran C. Differential diagnosis between mesothelioma and adenocarcinoma: A multimodal approach based on ultrastructure and immunocytochemistry. Sem Diagnost Pathol 1992; 9; 124-40.
10. Bedrossian C. Malignant mesothelioma and other pleural tumors. In: Pathology of Pulmonary Disease, Saldana M (ed), Philadelphia: Lippincott 1994; 657-71.
11. Barcat JA. Mucicarmín, P53 y mesoteliomas. Medicina (Buenos Aires) 1995; 55: 267-9.
12. Ordonez NG. The immunohistochemical diagnosis of mesothelioma. Am J Surg Pathol 1989; 13: 276-291.
13. Raghavan D, Gianousos P, Bishop J, Lee J, Young Y, Corte P. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-4.
14. Sugarbaker DJ, Heher EC, Lee TH, et al. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thoracic Cardiovas Surg 1991; 102: 10-8.
15. Boutin CM, Viallat JR, Vanzandwijk N, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67: 2033-7
16. Sugarbaker DJ, Jaklisch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: Who benefits?. Chest 1995; 107: 3495-505.
17. Rusch VW. Pleurectomy, decortication and adyuvant therapy for malignant mesothelioma. Chest 1993; 103 (Suppl): S-345.